Blood-brain barrier permeability and tPA-mediated neurotoxicity

Neuropharmacology

Volumn 58, Issue 7, 2010, Pages 972-980

  Fanne, Rami Abu ^a   Nassar, Taher ^b   Yarovoi, Sergei ^b   Rayan, Anwar ^c   Lamensdorf, Itschak ^d   Karakoveski, Michael ^e   Vadim, Polianski ^e   Jammal, Mahmud ^a   Cines, Douglas B ^b   Al Roof Higazi, Abd ^a,b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Baka El Garbiah   (Israel)

^d Thrombotech Ltd   (Israel)

^e PharmaSeed Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACTILASE; ALTEPLASE; N ACETYL ARGINYLMETHIONYLALANYLPROLYLGLUTAMYLGLUTAMYLISOLEUCYLISOLEUCYLMATHIONYLASPARTYLARGINYLPROLYLPHENYLALANYLLEUCYLPHENYLALANYLVALYLVALYLARGININE AMIDE; N ACETYLARGINYLMETHIONYLALANYLPHENYLALANYLGLUTAMYLGLUTAMYLISOLEUCYLISOLEUCYLMETHIONYLASPARTYLARGININE AMIDE; N ACETYLARGINYLMETHIONYLALANYLPROLYLGLUTAMYLGLUTAMYLISOLEUCYLISOLEUCYLMETHIONYLASPARTYLARGINYLPROLYLPHENYLALANYLLEUCYLPHENYLALANYLVALYLVALYLARGININE AMIDE; N ACETYLGLUTAMYLGLUTAMYLISOLEUCYLISOLEUCYLMETHIONYLASPARTIC ACID AMIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN DAMAGE; BRAIN ISCHEMIA; CATALYSIS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; EVOLUTIONARY HOMOLOGY; IN VITRO STUDY; IN VIVO STUDY; MORTALITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASODILATATION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MICE; MUTATION; PEPTIDE HYDROLASES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SERPINS; SIGNAL TRANSDUCTION; STROKE; THROMBOEMBOLISM; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77950935919     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.12.017     Document Type: Article

References (35)

1. Abola E.E., Sussman J.L., Prilusky J., Manning N.O. Protein data bank archives of three-dimensional macromolecular structures. Methods Enzymol. 1997, 227:556-571.
2. Adelson P.F., Whalen M.J., Kochanek P.M., et al. Blood-brain barrier permeability and acute inflammation in two models of traumatic brain injury in the immature rat: a preliminary report. Acta Neurochir. Suppl. 1998, 71:104-106.
3. Akkawi S., Nassar T., Tarshis M., Cines B.C., Higazi A.A.-R. LRP and avB3 mediate tPA-activation of smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1351-H1359.
4. Alafuzoff I., Adolfsson R., Grundke-Iqbal I., Winblad B. Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathol. 1987, 73:160-166.
5. Armstead W., Cines D., Higazi A.A.-R. Plasminogen activators contribute to age dependent impairment of NMDA cerebrovasodilation after brain injury. Develop. Brain Res. 2005, 156:139-146.
6. Armstead W.M., Nassar T., Akkawi S., Smith D.H., Chen X.H., Cines D.B., Higazi A.A.-R. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat. Neurosci. 2006, 9:1150-1155.
7. Byeon I.J., Llinás M. Solution structure of the tissue-type plasminogen activator kringle 2 domain complexed to 6-aminohexanoic acid an antifibrinolytic drug. J. Mol. Biol. 1991, 222:1035-1051.
8. Chen J., Sanberg P.R., Li Y., Wang L., Lu M., Willing A.E., Sanchez-Ramos J., Chopp M. Intravenous administration of human umbilical cord blood reduces rehavioral deficits after stroke in rats. Stroke 2001, 32:2682-2688.
9. Chen X., Gawryluk J., Wagener J., Ghribi O., Geiger J. Caffeine blocks disruption of blood-brain barrier in a rabbit model of Alzheimer's disease. J. Neuroinflammation 2008, 5:12. PMID: 18387175.
10. Choi D. Glutamate toxicity and diseases of the nervous system. Neuron 1988, 1:623-634.
11. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., Murray L.W., Arendall W.B., Snoeyink J., Richardson J.S., Richardson D.C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35:W375-W383.
12. Haj-Yehia A., Nassar T., Sachais B.S., Kuo A., Bdeir K., Al-Mehdi A.B., Mazar A., Cines D.B., Higazi A.A.-R. Urokinase-derived peptides regular vascular smooth muscle cell contraction in vitro and in vivo. FASEB J. 2000, 14:1411-1422.
13. Higazi A.A.-R., Ajawi F., Akkawi S., Hess E., Kuo A., Cines B.C. Regulation of the single-chain urokinase-urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity. Blood 2005, 105:1021-1028.
14. Higazi A.A.-R., Barghouti I.I., Abu-Much R. Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. J. Biol. Chem. 1995, 270:9472-9477.
15. Higazi A.A.-R., Bdeir K., Hiss E., Arad S., Kuo A., Barghouti I., Cines D.B. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. Blood 1998, 92:2075-2083.
16. Laskowski R.A. Structural quality assurance. Methods Biochem. Anal. 2003, 44:273-303.
17. Madison E., Goldsmith E., Gething M., Sambrook J., Gerard R. Restoration of serine protease-inhibitor interaction by protein engineering. J. Biol. Chem. 1990, 265:21423-21426.
18. Madison E.L., Goldsmith E.J., Gerard R.D., Gething M.J.H., Sambrook J.F., Bassel-Duby R.S. Amino acid residues that affect interaction of tissue plasminogen activator with plasminogen activator inhibitor 1. Proc. Natl. Acad. Sci. U S A 1990, 87:3530-3534.
19. Madison E.L., Goldsmith E.J., Gerard R., Gething M.J., Sambrook J. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 1989, 339:721-725.
20. Mori T., Wang X., Kline A.E., Siao C.J., Dixon C.E., Tsirka S.E., Lo E.H. Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma. Neuroreport 2001, 12:4117-4120.
21. Morris G.M., Goodsell D.S., Halliday R.S., Huey H., Hart W.E., Belew R.K., Olson J.A. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19:1639-1662.
22. Nagai N., De Mol M., Lijnen H.R., Carmeliet P., Collen D. Role of plasminogen system components in focal cerebral ischemic infarction. Circulation 1999, 99:2440-2444.
23. Nassar H., Lavi E., Akkawi S., Bdeir K., Heyman N.S., Raghunath O.N., Tomaszewski J., Higazi A.A.-R. Alpha-defensin: link between inflammation and atherosclerosis. Atherosclerosis 2007, 194:452-457.
24. Nassar T., Akkawi S., Shina A., Haj-Yehia A., Bdeir K., Tarshis M., Heyman S., Higazi A.A.-R. The in vitro and in vivo effect of tPA and PAI-1 on blood vessel tone. Blood 2004, 103:897-902.
25. Nicole O., Docagne F., Ali C., Margaill I., Carmeliet P., MacKenzie E.T., Vivien D., Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 2001, 7:59-64.
26. Renatus M., Engh R.A., Stubbs M.T., Huber R., Fischer S., Kohnert U., Bode W. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J. 1995, 16:4797-4805.
27. Ryu J., McLarnon J. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J. Cell Mol. Med. 2009, PMID: 18657226.
28. Sabel M., Rommel F., Kondakci M., Gorol M., Willers R., Bilzer T. Locoregional opening of the rodent blood-brain barrier for paclitaxel using Nd:YAG laser-induced thermo therapy: a new concept of adjuvant glioma therapy?. Lasers Surg. Med. 2003, 33:75-80.
29. Su J.E., Fredriksson L., Geyer M., Folestad E., Cale J., Andrae J., Gao Y., Pietras K., Mann K., Yepes M., Strickland K.D., Betsholtz C., Eriksson U., Lawrence A.D. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med. 2008, 14:731-737.
30. Tan Z., Li X., Kelly K., Rosen C., Huber J. Plasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusion. Brain Res. 2009, 1281:84-90.
31. Tejima E., Katayama Y., Suzuki Y., Kano T., Lo E.H. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke 2001, 32:1336-1340.
32. Tucker H.M., Mottonen J., Goldsmith E.J., Gerard R.D. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat. Struct. Biol. 1995, 2:442-445.
33. Wang Y., Tsirka S., Strickland S., Stieg P., Soriano S., Lipton S. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 1998, 4:228-231.
34. Yepes M. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000, 96:569-576.
35. Yepes M., Sandkvist M., Moore E.G., Bugge T.H., Strickland D.S., Lawrence D.A. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest. 2003, 112:1533-1540.